Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials

• by Jerry Bagel, Ranga Gogineni, Asif Shaikh, Mark G. Lebwohl

• March 16, 2026

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

• by Kerri Miller

• April 6, 2026

• 2 min

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

• by Kerri Miller

• April 17, 2026

• 6 min

Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

• by Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, Anna Balato, Angelo Valerio Marzano, Matteo Megna, Diego Orsini, Lidia Sacchelli, Santo Raffaele Mercuri, Emanuele Trovato, Serena Giacalone, Alexia Pedron, Marzia Caproni, Edoardo Cammarata, Aldo Cuccia, Andrea Altomare, Alexandra M. G. Brunasso, Valentina Dini, Simone Ribero, Nicola Zerbinati, Francesco Messina, Stefano Caccavale, Carlo G. Carrera, Luca Potestio, Viviana Lora, Andrea Carugno, Federico Bardazzi, Giovanni Paolino, Antonio Costanzo, Alessandra Narcisi, Mario Valenti

• March 16, 2026